Consumers Union Documents
- Consumers Union Letter to FDA Commissioner on Avandia drug safety
In light of the credible estimates of possible continuing harm to patients caused by Avandia (diabetes medication) and the fact that there are readily available alternative treatments, Consumers Union recommends that the FDA make a decision by May on whether the drug’s sales and use should continue in the U.S.
- Consumer Reports Releases Investigative Report on Drug Pricing
After intensive investigation into the driving forces behind drug pricing , CR uncovered five key reasons consumers are seeing their costs skyrocket.
- Tell the FDA and NIH to Enforce the Clinical Trial Reporting Law!
Medical research institutions, universities and hospitals violate a federal law by not reporting clinical trial results to a national registry of publicly and privately supported clinical studies of human participants.
- Guest post: Einstein, Secrecy and the Medical Board of California
Guest post by Rae Greulich, member of Consumers Union’s California Safe Patient Network “No problem can be solved from the same level of consciousness that created it.” –Albert Einstein In an attempt to drive home the responsibility of first line health care workers to care meticulously for hospital inpatients, a California physician asked his staff Continue Reading
- Safe Patient Project Director Makes Modern Healthcare’s “100 Most Influential People in Healthcare”
Lisa McGiffert, Director of Consumers Union’s Safe Patient Project, was recognized in Modern Healthcare’s “100 Most Influential People in Healthcare” list. We couldn’t be more proud.
- Consumer Reports Survey Shows Americans Affected by Drug Price Increases
One third of Americans in a recent Consumer Reports poll are facing higher prices for their medications. Our advice can help you avoid sticker shock.
Research and Reports
- Drug Safety: FDA Has Conducted More Foreign Inspections and Begun to Improve Its Information on Foreign Establishments, but More Progress Is Needed
The GAO has written a report on the FDA’s progress on foreign drug inspections since 2008. In 2008, the GAO found that FDA had inspected relatively few foreign establishments and had inaccurate information in its databases from 2002 through 2007.
- Drug shortages: National survey reveals high level of frustration, low level of safety
ISMP survey: More than 1,000 near misses, errors, and adverse outcomes due to drug shortages in the US.